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Summary
 Background: We assessed prevalence and resistance of uropathogens on antimicrobial agents (AA) from urine 
cultures (UC) in children hospitalized with urinary tract infections (UTI) at University Hospital 
in Split.
 Material/Methods: During the 7-year period, children hospitalized only once with UTI alone were compared to those 
repeatedly hospitalized, and who received long-term antimicrobial prophylaxis (LTAP), as well as 
those with associated anomalies of the urinary system (US).
 Results: E. coli was the most frequent isolate (67.7%) with resistance to ampicillin by 69.5%, amoxicillin/cla-
vulonic acid by 3.5%, cephalexin by 6.6%, trimethoprim/sulfamethoxazole (TMP-SMX) by 27.5%, 
and nitrofurantoin by 0.4%. For other uropathogens, AA resistance rates were the following: 64.3%, 
5.8%, 10.5%, 21.3%, and 7.9%. The high or increasing resistance to TMP-SMX is characterized by 
all uropathogens. Patients with anomalies of US showed a lower prevalence of E. coli and Enterococcus 
sp., but a higher prevalence of Pseudomonas sp., ESBL-producing E. coli and Klebsiella sp. than those 
without US anomalies. Repeatedly hospitalized patients showed a lower prevalence of E. coli, but a 
higher prevalence of Pseudomonas sp. and Klebsiella sp. than patients hospitalized only once. Both 
groups displayed significantly less resistance of Enterococcus sp. In patients receiving LTAP before 
hospitalization, E. coli was significantly more resistant to ampicillin, amoxicillin/clavulonic acid 
and TMP/SMX than in those without LTAP.
 Conclusions: Based on our results, we recommend excluding ampicillin altogether, and reconsideration of fur-
ther use of TMP-SMX, as well as use of nitrofurantoin, cephalexin and amoxicillin/clavulonic acid 
for LTAP in our region.
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Background
Urinary tract infection (UTI) is a significant cause of morbid-
itiy among children, and may result in permanent parenchy-
mal damage with the possible development of late complica-
tions such as arterial hypertension or chronic renal failure. 
The likelihood of developing these late complications in 
UTIs is the greatest in the first year of life, but gradually de-
creases in older children [1,2]. Following the treatment of 
a full dose of antibiotics for symptomatic UTI, long-term an-
tibacterial prophylaxis (LTAP) is applied. The aim of LTAP 
is to prevent a recurring urinary infection and the potential 
for permanent tissue damage. Recurrent UTI with or with-
out vesico ureteral reflux in children is the most frequent 
indication for LTAP [2,3]. The idea of LTAP is to provide 
small levels of antimicrobial agents (AA) in the urinary sys-
tem, sufficient to prevent bacterial multiplication [4]. Aside 
from some controversies regarding the use of LTAP, widely 
accepted indications for LTAP are as follows: vesico ureteral 
reflux, recurrent UTI with or without associated anomalies, 
febrile UTI in the first year of life, prenatal hydronephrosis 
due to obstruction or vesico ureteral reflux, and UTI asso-
ciated with voiding disturbances or the weakness of the im-
mune system. LTAP is usually administered in a single daily 
dose equivalent to a quarter or half of the conventional ther-
apeutic dose. The most commonly prescribed medication 
is nitrofurantoin in children after the first year of life and 
trimethoprim/sulfamethoxazole (TMP/SMX) in children 
older than 3 months. For newborns and infants less than 3 
months of age, prescribed antibiotics for LTAP are amoxi-
cillin/clavulonic acid and cephalosporins. However, quino-
lones are not regularly prescribed in children [3]. Limitations 
of LTAP include relative ineffectiveness, increasing microbi-
al resistance rates that are proportionate to the duration of 
treatment, adverse effects, poor compliance and cost [3,5]. 
Some authors reported a growing bacterial resistance to com-
mon AAs used in LTAP [6–11]. Other authors have reported 
an increasing rate of bacterial resistance to AAs in patients 
who had anatomic or functional abnormalities of the US, 
as well as those patients who were repeatedly hospitalized 
for UTI [11,12]. Nowadays, various recommendations exist 
concerning indications for LTAP in comparison to previous 
guidelines. Some authors do not recommend prophylaxis 
after a single UTI in infancy [13–15], a surprising position 
in light of the fact that in the first year of life the frequency 
of febrile UTI is highest, as well as the susceptibility of per-
manent parenchymal damage [16]. In cases of prescribed 
LTAP, there is still no consensus about the duration of treat-
ment. A variety of guidelines have been proposed regarding 
the age of patients, grade of vesico ureteral reflux, any co-
existing anatomic anomalies of urinary tract, the frequen-
cy of UTI and size of renal scarring. Furthermore, careful 
monitoring of each patient is recommended in order to de-
tect UTI as early as possible, as well as treating the patient 
with the proper antibiotic and changing the antibiotic in the 
case of a recurrent UTI [3,14]. Although prophylactic use 
of antibiotics in pediatric nephrology has been commonly 
accepted and used all over the world, some recent studies 
question the effectiveness of LTAP in the prevention of UTI 
and renal scarring, stressing the great need for new well-de-
signed studies, whose results would give new insight in an-
tibiotic use in LTAP [4,6,7,17,18]. The American Academy 
of Pediatrics (1999) and Matoo (2007) proposed several 
medications and their doses for LTAP [1,3]. We suspected 
that some of the proposed medications would have a high 
percentage of bacterial resistance in our local communi-
ty; therefore we decided to undertake our own study in or-
der to assess the situation regarding bacterial resistance in 
University Hospital in Split. We will also give some recom-
mendations regarding the choice of drugs for LTAP in our 
region. In addition, we investigated the prevalence of uro-
pathogens isolated from urine cultures in children hospi-
talized with UTI at the Department of Pediatrics during the 
7-year study period.
The purpose of this study was to evaluate changes in bacteri-
al resistance patterns among 3 specific patient populations: 
patients on/off LTAP, patients with multiple/single hospi-
talization and patients with/without functional or anatom-
ic abnormalities of the urinary system. Finally, we compared 
our results with those from other studies and deduced our 
own recommendations for antibiotic use.
Material and Methods
We retrospectively reviewed the charts of all 1158 patients 
hospitalized for UTI at University Hospital in Split between 
2000 and 2007.
UTI was confirmed by a positive urine culture of 105 or more 
colony-forming units of a single organism per milliliter of urine. 
Isolates were initially recovered on blood agar plates from urine 
samples. The initial identification of a pure bacterial culture 
was made by using convential biochemical tests and was con-
firmed by Vitek 2 systems (bioMerieux, Marc Marcyl’Etoile, 
France). Routine susceptibility testing to antibiotics was made 
by disk-diffusion tests, according to CLSI recommendations.
We recorded the patient’s pertinent medical history, includ-
ing the number of hospitalizations for UTI, possible treat-
ment of LTAP in the last 6 months before hospitalization, the 
presence of acute or chronic infection, and the presence of 
any anatomic or functional anomalies of the urinary system 
such as vesico ureteral reflux, neurogenic bladder, or oth-
er anatomic abnormalities. In this study, acute UTI was de-
fined as the patient’s first UTI with no signs of permanent 
damage of the urinary system. At the same time, chronic 
UTI was defined as permanent or recurrent UTI with def-
inite damage to the urinary system. Functional anomaly of 
the urinary system was defined as a change in function of 
the lower urinary system, resulting in dysfunctional voiding.
Statistical analysis
In the statistical analysis of data we used a c2 test with P<0.05 
as a statistically significant value and Spearman’s correla-
tion test.
results
From the group of 1158 children with UTI, hospitalized at 
our Department, 1355 positive urine cultures were isolated.
E. coli was isolated in 917 cases (67.7%), Enterococcus in 
164 isolates (12.1%), Klebsiella sp. in 110 isolates (8.1%), 
Proteus sp. in 67 isolates (4.9%), Pseudomonas sp. in 64 iso-
lates (4.6%), and other bacteria were isolated in the remain-
ing 33 cases (2.3%).
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The mean resistance rates of the most prevalent E. coli were as 
follows: 69.5% to ampicillin, 3.5% to amoxicillin/clavulonic 
acid, 6.6% to cephalexin, 27.5% to TMP/SMX, and 0.4% to ni-
trofurantoin. During the study period, follow-up of the trends 
in resistance rates of E. coli to antimicrobial agents disclosed 
a statisticaly significant positive trend to TMP/SMX (r=0.762; 
P=0.028), a statisticaly significant negative trend to cephalex-
in (r=–0.786; P=0.021), while no significant trends were de-
tected to ampicillin (r=–0.120; P=0.776) and nitrofurantoin 
(r=–0.192; p=0.648). We also proved 93% probability of a nega-
tive trend in the resistance rate of E. coli to amoxicillin/clavulo-
nic acid (r=–0.66; P=0.075) during the study period (Figure 1).
The mean resistance rates of all isolated uropathogens to 
common AAs were the following: 64.3% to ampicillin, 5.8% 
to amoxicillin/clavulonic acid, 10.5% to cephalexin, 21.3% 
to TMP/SMX, and 7.9% to nitrofurantoin.
Follow-up of the trends in resistence rates of all uro-
pathogens to antimicrobial agents during the study pe-
riod disclosed statisticaly significant negative trends to 
cephalexin (r=–0.934; P=0.001) and to amoxicillin/cla-
vulonic acid (r=–0.802; P=0.017), while no significant 
trends were detected to ampicillin (r=0.143; P=0.736) 
and TMP/SMX (r=0.419; P=0.301). For nitrofurantoin, 
we found a 90% probability of a negative trend in resis-
tance rates for all uropathogens during the study period 
(r=–0.618; P=0.102). However, resistance to TMP/SMX 
increased from 2004 to 2006, but not during the entire 
study period. Pseudomonas sp. and Enterococcus were not 
included in these results due to the fact that they have 
not been tested by all the AAs.
Among the group of 324 children with functional or anatom-
ic abnormalities, there were 27 cases of functional anoma-
lies of the lower urinary system, 47 cases of hydronephrosis, 
35 cases of duplex collecting system, 11 cases of urolithiasis, 
116 cases of vesico ureteral reflux, and 29 cases of other an-
atomic anomalies of the urinary system. Fifty-nine patients 
underwent surgery on the urinary system. Pseudomonas was 
3 times more common while Enterococcus was 2 times less 
common in patients with functional or anatomic anoma-
lies of the urinary system than in patients with normal uri-
nary systems (Figure 2).
In the group of children with normal urinary tracts, 113 cas-
es of Enterococcus sp. were found to be resistant to 5 tested 
AAs (37%), but were susceptible in 196 cases (63%). While 
in the group of children who had abnormalities of the uri-
nary tract, 20 isolated strains of Enterococcus sp. were found 
to be resistant to the 5 tested AAs (24%), but were suscep-
tible in 63 cases (76%). This means that the isolated strains 
of Enterococcus sp. were 1.5 times more resistant to the tested 
AAs in the group of children who had normal urinary sys-
tems than the group of children who had anatomic or func-
tional abnormalities of the urinary system (c2=4.5; P=0.033).
In the group of patients with a normal urinary system, iso-
lated strains of Klebsiella sp. were resistant to 45 of the tested 
AAs (29%) and were susceptible to 109 (71%), while in the 
group of patients who had abnormalities of urinary tract, iso-
lated strains of Klebsiella sp. were resistant to 36 of the tested 
AAs (40%) and were susceptible to 53 of those AAs (60%). 
This means that the isolated strains of Klebsiella sp. were 1.4 
times more resistant to AAs in patients with anatomical or 
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Figure 1.  This figure shows that resistant rates of E. coli to various 
uroantiseptic drugs were the highest for ampicillin and 
TMP/SMX. During the period of observance E. coli’s 
resistance to TMP/SMX had significantly increasing trend, 
to cephalexin had significantly decreasing trend while to 
amoxicillin/clavulonic acid had 93% probability to have 
decreasing trend. Resistance rates of E. coli did not change 
significantly to ampicillin and to nitrofurantoin during the 
period of observance. Spearman’s correlation coefficient 
(ρ) and χ2 (p) were as follows: to ampicillin (ρ=–0.120; 
p=0.776), to TMP/SMX (ρ=0.762; p=0.028), to cephalexin 
(ρ=–0.786; p=0.021), amoxicillin/clavulonic acid 
(ρ=–0.66; p=0.075), and to nitrofurantoin (ρ=–0.192; 
p=0.648).
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Figure 2.  This figure shows significantly higher 
prevalence of Pseudomonas sp. and 
significantly lower prevalence of 
Enterococcus sp. in patients with 
functional or anatomic anomalies of 
urinary system.
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functional anomalies of urinary system than in those with 
a normal urinary system (c2=3.2; P=0.074).
In this study the prevalence of uropathogens in terms of the 
number of hospitalizations showed that patients hospital-
ized more than once had a lower chance of having isolated 
E. coli. However, they had approximately a 3 times greater 
frequency of UTI caused by Pseudomonas sp. and a 2 times 
greater frequency of UTI caused by Klebsiella sp. than pa-
tients who were hospitalized only once (Figure 3).
In the group of children who were hospitalized only once, 
isolated strains of Enterococcus sp. were resistant to 115 of 5 
tested AAs (37%) and were susceptible to 193 of those AAs 
(63%), while in the group of patients who had multiple hos-
pitalizations, the isolated strain of Enterococcus sp. was resis-
tant to 18 of 5 tested AAs (21%) and were susceptible to 66 
(79%). This means that isolated strains of Enterococcus sp. 
were 1.7 times more resistant to AAs in patients who were 
admitted to the hospital only once than in those who were 
hospitalized more than once (c2=7.45; P=0.006).
As opposed to the results obtained in Enterococcus sp., the 
isolated strains of ESBL-producing Klebsiella sp. in children 
with multiple hospitalizations were 1.4 times more resistant 
to antibiotics than the strains isolated in the group of chil-
dren who were admitted only once. The isolated strains of 
ESBL-producing Klebsiella sp. in the children upon their 
first hospitalization were resistant to 107 of the 5 tested 
AAs (53%) and were susceptible to 95 (47%), while in 
the group of children with repeated hospitalizations iso-
lated ESBL-producing Klebsiella sp. were resistant to 61 of 
the 5 tested AAs (68%), and were susceptible to 28 (32%), 
c²=6,14, P=0.013.
Out of all the patients who were admitted to the Pediatric 
Department for an UTI, a group of 175 children received 
various AAs for LTAP prior to hospitalization at the prima-
ry health care level (Table 1).
The resistance rates of E. coli to some AAs were significant-
ly different between the groups of children who received 
LTAP and those who did not receive LTAP. That difference 
was most significant in the administering of TMP/SMX. We 
found an approximately 2 times greater resistance rate in 
patients who received LTAP prior to hospitalization than in 
those who did not receive LTAP at all. Moreover, resistance 
to nitrofurantoin in both groups was very low (Table 2). The 
probability that E. coli would be more resistant in patients 
who had previously undergone LTAP than in those who did 
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Figure 3.  This figure shows significantly higher 
prevalence of Pseudomonas sp. and 
Klebsiella sp. in patients who were 
hospitalized for UTI more than once.
Medication Number of patients (%)
TMP/SMX  56 (32)
Nitrofurantoin  34 (19.3)
TMP/SMX /nitrofurantoin  14 (8)
Cephuroxime  31 (17.7)
Amoxicillin  12 (6.7)
Cephalexin  14 (8.0)
Amoxicillin-clavulonic acid  8 (4.5)
Other antimicrobial drugs*  7 (4)
Total  175 (100)
Table 1.  The distribution of the most frequently used AA for LTAP at 
the primary health care level among hospitalized patients 
during the period from 2000 to 2007.
 * Other antimicrobial drugs: cephtibuten, cephyxime, ampicillin.
Antibacterial 
agent
Group: No LTAP 
(n=801)
Group: 
LTAP (n=114)
Resistance rate n 
(%)
Resistance rate n 
(%)
Ampicillin  548 (68.40%)  89 (78.10%)
Amoxycillin- 
clavulanic ac.  25 (3.10%)  8 (7.00%)
Cephalexin  54 (6.70%)  7 (6.10%)
TMP/SMX  202 (25.20%)  53 (46.50%)
Nitrofurantoin  3 (0.40%)  1 (0.90%)
Table 2.  Comparison of resistance rates of E. coli isolates to AA 
between the groups of children who received LTAP previously 
and those who were not treated by LTAP.
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not was proven significant for ampicillin (c2=3.83; P=0.05), 
for amoxicillin/clavulonic acid (c2=4.29; P=0.038) and to 
TMP/SMX (c2=23.4; P<0.01).
discussion
E. coli was generally found to be the most frequent cause of 
UTI in hospitalized (40–90%), as well as in non-hospital-
ized (63–78%) children [8–10,12,19–21]. The mean preva-
lence of isolated E. coli in our study during the observed pe-
riod (2000–2007) was 67.5%; the highest being in year 2002 
(73.7%), but the lowest in year 2007 (60.4%).
As also reported in previous studies that the incidence 
of E. coli was lower in the cases of multiple hospitaliza-
tions, in patients previously treated with LTAP, as well as 
in cases with coexisting urinary tract anomalies that al-
lowed the increasing growth of some less common uro-
pathogens [8,12].
Incidence of uropathogens in children with urinary tract 
anomalies and multiple hospitalizations
In our study the incidence of E.coli was slightly less in pa-
tients with urinary tract anomalies (61.9%) (Figure 2), as 
well as in patients with multiple hospitalizations (52.6%) 
(Figure 3), as opposed to patients with normal urinary 
tracts and those who were hospitalized only once for UTI.
The incidence of Enterococcus also decreased in patients 
with urinary tract anomalies. On the contrary, throughout 
the entire study period, the incidence of Pseudomonas sp. 
was 3 times greater in children with urinary tract anoma-
lies as well as in those with multiple hospitalizations. In ad-
dition, isolated Klebsiella sp. were 2 times more frequent in 
the group of patients with multiple hospitalizations than in 
patients hospitalized only once (Figure 3).
Resistance rates of uropathogens to antimicrobial agents
In the American study by Lutter et al. (2005), performed 
during 1997–2001, the resistance rates of all isolates ranged 
from 48% to ampicillin, 17% to TMP/SMX and 7% to ni-
trofurantoin. In Taiwan, Tseng et al. (2008) reported 77.4% 
resistance to ampicillin, 44.6% to TMP/SMX, 27.2% to 
cephalotin, and 8.4% to nitrofurantoin, with growing re-
sistance rates to ampicillin, TMP/SMX, and cephalospo-
rins in the first generation during the 14-year study pe-
riod [8,20].
In accordance with the above-mentioned studies, our re-
sults showed a similarly high resistance rate to ampicillin 
(45–62%), and a growing resistance to TMP/SMX (from 
15% in 2000 to 35% in 2006). During the same period, the 
resistance of all uropathogens to nitrofurantoin remained 
low, while the resistance of E. coli to nitrofurantoin was even 
lower (Figure 1). Besides the relatively high resistance rate 
to ampicillin and TMP/SMX, resistance rates of all isolates, 
except Pseudomonas sp. and Enterococcus sp., showed a de-
creasing trend in first-generation cephalosporins (cepha-
lexin) and amoxicilin-clavulonic acid. These changes in re-
sistance could be explained by the extensive consumption 
of antibiotics, especially azitromicyn and third-generation 
cephalosporins, which were over the previous years widely 
prescribed for various indications in our region locally as 
well as in the entire country [1–3].
Regarding resistance of E. coli, our study showed that the re-
sistance rate to ampicillin was continuously high (a mean of 
69.5%), with the highest rate being in year 2001 (78.6%). 
During the same period of time, resistance rates to amox-
icilin-clavulonic acid and cephalexin decreased, similar to 
the trends observed in all the other isolates. However, the 
increasing resistance rate of E. coli to TMP/SMX was higher 
than the resistance to all other isolated uropathogens, first 
showing increasing trends until year 2004, but later show-
ing a decrease in year 2007 (Figure 1). This increasing re-
sistance rate might be explained by the widespread pre-
scription of TMP/SMX for treatment of UTI and providing 
LTAP in Croatia. Increasing resistance rates to TMP/SMX 
was not uncommon in other countries all over the world 
[1–3]. On the contrary, permanently low resistance rates 
to nitrofurantoin, with an average value of 0.4%, could be 
associated with the infrequent prescription of this drug. 
Our results show a decreasing trend of resistance of E. coli 
to amoxicillin/clavulonic acid and cephalexin, but a low 
resistance to nitrofurantoin, in accordance with trends 
in other parts of Croatia, as reported by the Committee 
for Monitoring Bacterial Resistance Rates of the Croatian 
Academy of Medical Sciences [19]. Similar results of antibi-
otic resistance were reported in Canada and Brazil [11,22].
Permanently high resistance to antibiotics with increasing 
resistance rates of E. coli to ampicillin and TMP/SMX were 
shown in studies from the UK, Austria, Spain and Brasil 
[9,11,12,1923]. Because of that, some authors concluded 
that ampicillin, trimetoprim, and TMP/SMX were insuf-
ficient for the monotherapy of UTI, as recommended by 
Wolff et al (2007) [9,24]. Furthermore, Cheng CH et al. 
(2008) warned that the use of cephalosporins in LTAP could 
increase the number of UTIs caused by ESBL-producing 
bacteria or multidrug-resistant uropathogens other than 
E. coli, therefore they suggested keeping TMP/SMX for 
use in LTAP [25].
Resistance to antimicrobial therapy in children with 
abnormalities of the urinary tract
In children with functional or anatomic urinary tract ab-
normalities, we expected to find more resistant patho-
gens, presuming that they probably had frequent exacer-
bations of UTI and received long and frequent antibiotic 
treatment. Our study fulfilled these expectations partly 
for Klebsiella sp. (probability of 97% to be more resistant 
to AAs), while Enterococcus showed that patients had signif-
icantly more resistant strains of that uropathogen than if 
they had normal urinary systems. However, other isolated 
uropathogens in that group of patients were not signifi-
cantly more resistant to AAs as compared to patients with 
normal urinary systems. In contrast to our results, Ladhani 
and Grandsen (2003) found higher resistance rates of E. 
coli to ampicillin, amoxicillin/clavulonic acid, nitrofuran-
toin, and TMP/SMX in the group of patients with under-
lying renal problems compared to patients with normal 
urinary systems [12]. A study made by Allen et al. (1999) 
proved that children with urinary abnormalities had a 2.4 
times higher chance of acquiring a UTI caused by E. coli 
that was resistant to TMP/SMX (11).
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Resistance to antimicrobial therapy in repeatedly 
hospitalized children
Although we expected that some uropathogens from our 
study would disclose higher resistance rates to AAs in pa-
tients who were repeatedly hospitalized for UTI than those 
hospitalized only once, we confirmed those expectations in 
ESBL-producing Klebsiella sp. alone. Our results contradict-
ed Allen’s study, claiming that children with 2 or more hos-
pital admissions were 4 times more likely to have a resistant 
isolate of E.coli than those who had no admissions in the 
previous year [11]. Moreover, we found that Enterococcus was 
1.7 times more resistant to tested AAs in patients who were 
admitted to the hospital only once.
Resistance to antimicrobial therapy in children receiving 
LTAP
Our study also showed that resistance rates of E. coli to AAs 
could be altered if patients had been receiving LTAP for 
up to 4 weeks within the last 6 months prior to hospitaliza-
tion. The resistance rates of E. coli to TMP/SMX, ampicillin 
and amoxicillin/clavulonic acid were significantly higher in 
the group of children in this study who had received LTAP 
compared to those who had not. This is in accordance with 
Allen’s study (1999) showing a 23 times greater chance of 
getting a UTI caused by E. coli resistant to TMP/SMX. These 
patients received LTAP prior to hospitalization. Lutter’s 
study (2005) showed the same result in patients affected 
by all kinds of uropathogens [8,11]. Contrary to those re-
sults, resistance to nitrofurantoin in both groups from our 
study retained very low levels. Unexpectedly, the resistance 
rate of E. coli to cephalexin in children who received LTAP 
was even lower (4.9%) than in children who did not re-
ceive LTAP (6.8%). Some studies claimed that LTAP with 
TMP/SMX and ampicillin was ineffective in the prevention 
of UTI and kidney damage, as well as its connection to the 
increased risk of UTIs caused by resistant uropathogens in 
some categories of patients [6,7,9,10].
The use of low-dose prophylactic antibiotics to prevent re-
current UTI and kidney damage has been the standard 
care for many children with urinary tract anomalies, espe-
cially VUR [4]. In the last few years, some studies have ex-
pressed serious doubts concerning the efficiency of LTAP, 
but without providing convincing evidence against LTAP so 
far. Therefore, LTAP is still recommended [6,13,14,26] with 
customarily prescribed TMP/SMX, nitrofurantoin, cepha-
lexin, ampicillin, and amoxicillin [1–3,6]. In our study, ap-
proximately 40% of the children received TMP/SMX for 
LTAP for different causes, alone or with other AAs. This per-
centage is lower in comparison to some other studies that 
used TMP/SMX – 61–100% of cases [7,10,12,17]. Apart 
from TMP/SMX, our patients received nitrofurantoin in 
27.3% of cases and cephalosporins in 25% alone or alter-
nating with another AA (Table 1). In comparison to other 
studies, nitrofurantoin was used in only 0–18%, and ceph-
alosporins in 0–3% of cases receiving LTAP [7,10,12,17].
conclusions
We believe that, based on our own data regarding resis-
tance patterns of uropathogens in our local community, 
we should influence primary care doctors by encouraging 
them to prescribe more effective drugs in order to achieve 
better effects of LTAP. In cases where LTAP is undoubted-
ly prescribed, it should be administered according to the 
resistance patterns on a local level. This is the best way to 
choose optimal LTAP. Nevertheless, local studies on resis-
tance patterns of uropathogens should be encouraged in 
the future. We believe that there is still room for conduct-
ing efficient LTAP if we change AAs according to the lo-
cal results of resistant patterns, otherwise we are forced to 
follow the general recommendations for LTAP, which are 
not always appropriate and effective in specific local com-
munities [1,2,13]. In that sense, our recommendation is to 
exclude ampicillin from further LTAP and reconsider the 
use of TMP/SMX. In addition, we recommend the use of 
amoxicillin/clavulonic acid and/or cephalexin in the first 
3 months of life, and nitrofurantoin after the first year of 
life, whenever possible. The duration of LTAP is another 
not yet resolved issue. In conclusion, we are strongly con-
vinced that if doctors at the primary medical care level were 
encouraged to carry out our recommendations, results of 
LTAP at the local level would greatly improve.
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